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Background:  A  community-based  randomized  trial  was  conducted  in  Costa  Rica  to  evaluate  the HPV-
16/18  AS04-adjuvanted  vaccine  (NCT00128661).  The  primary  objective  was  to evaluate  efﬁcacy  of  the
vaccine  to prevent  cervical  intraepithelial  neoplasia  2 or more  severe  disease  (CIN2+)  associated  with
incident  HPV-16/18  cervical  infections.  Secondary  objectives  were  to evaluate  efﬁcacy  against  CIN2+
associated  with  incident  cervical  infection  by any  oncogenic  HPVs  and  to evaluate  duration  of  protection
against  incident  cervical  infection  with  HPV-16/18.  Vaccine  safety  and  immunogenicity  over  the  4-year
follow-up  were  also  evaluated.
Methods:  We  randomized  (3727  HPV  arm; 3739  control  arm),  vaccinated  (HPV-16/18  or Hepatitis  A)  and
followed  (median  53.8 months)  7466  healthy  women  aged  18–25  years.  5312  women  (2635 HPV  arm;
2677  control  arm)  were  included  in  the  according  to protocol  analysis  for  efﬁcacy.  The full cohort  was
evaluated  for  safety.  Immunogenicity  was  considered  on  a subset  of 354  (HPV-16)  and  379 (HPV-18)
women.  HPV  type  was  assessed  by  PCR  on cervical  specimens.  Immunogenicity  was  assessed  using ELISA
and inhibition  enzyme  immunoassays.  Disease  outcomes  were  histologically  conﬁrmed.  Vaccine  efﬁcacy
and 95%  conﬁdence  intervals  (95%CI)  were  computed.
Results: Vaccine  efﬁcacy  was  89.8%  (95%  CI: 39.5–99.5;  N = 11  events  total)  against  HPV-16/18  associated
CIN2+,  59.9%  (95%  CI: 20.7–80.8;  N  =  39  events  total)  against  CIN2+  associated  with  non-HPV-16/18  onco-
genic  HPVs  and  61.4%  (95%  CI: 29.5–79.8;  N  = 51  events  total)  against  CIN2+  irrespective  of HPV  type.  The
vaccine  had  an  acceptable  safety  proﬁle  and  induced  robust  and  long-lasting  antibody  responses.
Conclusions:  Our ﬁndings  conﬁrm  the  high  efﬁcacy  and immunogenicity  of  the  HPV-16/18  vaccine  against
incident  HPV  infections  and  cervical  disease  associated  with  HPV-16/18  and  other  oncogenic  HPV types.
These  results  will  serve  as  a benchmark  to which  we  can  compare  future  ﬁndings  from  the  ongoing
extended  follow-up  of  participants  in the  Costa  Rica  trial.
Trial  registration:  : Registered  with  clinicaltrials.gov:  NCT00128661.
Published  by Elsevier  Ltd. This is  an  open  access  article  under  the  CC  BY-NC-SA  license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).
Abbreviations: ATP, according to protocol; AE, adverse event; CI, conﬁdence interval; CIN2+, cervical intraepithelial neoplasia 2 or more severe disease; CVT, Costa Rica
PV-16/18 vaccine trial; GMT, geometric mean titer; HPV, human papillomavirus; DEIA, SPF10 HPV DNA enzyme immunoassay; EIA, inhibition enzyme immunoassay; ELISA,
nzyme-linked immunosorbent assay; NCI, National Cancer Institute; SAE, serious advers
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. Introduction
Three programs launched in the 2000s evaluated prophylac-
ic virus-like particle (VLP) human papillomavirus (HPV) vaccines
1–3]. Two of these programs were led by manufacturing compa-
ies, Merck Pharmaceuticals and GlaxoSmithKline Biologicals, who
icensed the HPV-VLP technology and developed vaccines to pre-
ent cervical cancers caused by HPV-16 and HPV-18, two  HPV types
hat account for up to 70% of cervical cancers worldwide. Results
rom trials by these companies demonstrated that the vaccines
ave an acceptable safety proﬁle and are highly effective for the
revention of HPV infections and lesions associated with vaccine
ypes, and in some instances to additional, related types. As a result,
oth vaccines are licensed for use in adolescents and young adults
n many countries [4–10].
The third program initiated pre-licensure was a community-
ased trial in Costa Rica (NCT00128661) sponsored by the
S National Cancer Institute (NCI) that utilized the HPV-16/18
S04-adjuvanted vaccine (Cervarix®, hereafter referred to as the
PV-16/18 vaccine) provided to NCI by GlaxoSmithKline Biologi-
als [11]. This trial was designed to evaluate the efﬁcacy, safety,
mpact and immune mechanisms associated with HPV vaccina-
ion, and to extend natural history studies to vaccinated groups.
o date, results from the Costa Rica HPV-16/18 vaccine trial (CVT)
ave shown that (1) the vaccine is highly effective at preventing
ew persistent infections with HPV-16/18 [12], (2) the vaccine con-
ers partial protection against HPV types phylogenetically related
o HPV-16/18 [13], (3) the vaccine does not help treat infections
14], (4) fewer than 3 doses of the vaccine appear to protect as
ell as the full 3-dose series for at least 4 years against per-
istent HPV-16/18 infections [15], (5) there are indications that
he vaccine protects against HPV infection at the anus and oral
avity [16,17], (6) the vaccine does not impact overall rates of
regnancies/pregnancy outcomes [18], (7) the impact of vacci-
ation declines with increasing age at vaccination [12], (8) the
nitial impact of young adult vaccination on colposcopy refer-
al/treatment rates in well-screened populations are modest [19],
9) within the same age group, levels of antibodies achieved long-
erm following two doses (0 and 6 months) of the vaccine are high
nd only slightly lower than those observed after three doses and
ntibodies achieved long-term following one dose of the vaccine
re lower than those observed with 3 doses but stable [20], (10) vac-
ination induces cross-neutralizing potential in sera of vaccinees
21], and that (11) modest antibody levels generated by natural
PV infection provide partial protection against re-infection [22].
We now extend those ﬁndings by presenting results from the
linded analysis conducted at the end of the ﬁrst four years of
ollow-up. These results focus on the according to protocol (ATP)
fﬁcacy ﬁndings submitted to the FDA under BB-IND #7920; sepa-
ate submissions focus on ﬁndings from intent-to-treat and naïve
nalyses from our trial [12,23].
. Materials and methods
.1. Design, subjects, procedures, and testing
This analysis presents a double-blind randomized controlled
rial of an HPV-16/18 vaccine among healthy women 18–25 years
ld. The study was approved by the Institutional Review Boards in
osta Rica and the US. Detailed methods have been published [11].
n brief, potential participants from a census were invited between
une 2004 and December 2005. Eligible women who agreed to par-
icipate (N = 7466; estimated to provide >80% power to observe
xpected differences between arms) were randomized with equal
hance to the HPV-16/18 (HPV arm) or Hepatitis A vaccine (control 32 (2014) 5087–5097
arm), offered in three doses over approximately six months. Blind-
ing to arm assignment was  maintained throughout the 48-month
follow-up and until the analytic dataﬁle was frozen.
At enrollment, a pelvic exam was performed on sexually expe-
rienced women. Exfoliated cells were collected for cytology, HPV
DNA, and other tests. At the 6-month visit, women were asked to
provide a self-collected cervical specimen for HPV testing. Blood
was collected from participants. Each participant was scheduled
for annual follow-up examinations (median follow-up time = 53.8
months; inter-quartile range: 50.5–57.0), at which time a pelvic
examination was performed on sexually active women, and exfo-
liated cells and blood were collected. On a pre-deﬁned subset, an
additional visit approximately one month following the last vaccine
dose was  performed where blood was  collected for immunological
assessment.
Cytology was  classiﬁed using the Bethesda system. Women  with
low-grade squamous intraepithelial lesions (LSIL) or HPV positive
atypical squamous cells of undetermined signiﬁcance (ASC-US)
were followed semi-annually. The colposcopy referral algorithm
used in our trial parallels that used for the PATRICIA trial [6].
Speciﬁcally, a repeat LSIL/HPV positive ASC-US, an ASC-US-rule
out high-grade SIL (ASC-H), high-grade squamous intraepithelial
lesions or more severe disease (HSIL+), or glandular abnormalities
prompted colposcopy and treatment as needed [11].
HPV testing using the Hybrid Capture 2 test was performed
on enrollment specimens plus specimens from women with an
ASC-US cytology during follow-up for clinical management [11].
Broad spectrum PCR-based HPV DNA testing was performed on
specimens based on ampliﬁcation and broad spectrum probe
hybridization using the SPF10 HPV DNA enzyme immunoassay sys-
tem followed by typing using the LiPA25 version 1 line detection
system and HPV-16 and -18 type speciﬁc testing [11]. Enzyme-
linked immunosorbent assay (ELISA) was used to detect and
quantify IgG antibodies against HPV-16 and -18 in the subset
of women  selected for the extra visit one month after the last
vaccination dose [4,24]. Immunogenicity was also assessed by a
V5/J4 monoclonal antibody inhibition enzyme immunoassay (EIA),
which in contrast to the ELISA detects speciﬁc neutralizing epitopes
[24,25].
2.2. Objectives
The primary objective was  to evaluate efﬁcacy of the vaccine to
prevent cervical intraepithelial neoplasia 2 or more severe disease
(CIN2+) associated with incident (post dose 3) HPV-16/18 cervi-
cal infections. Secondary objectives were to evaluate efﬁcacy to
prevent CIN2+ associated with incident cervical infection by any
oncogenic HPV type and to evaluate the duration of protection
conferred by the vaccine against incident cervical infection with
HPV-16/18. Vaccine safety and immunogenicity over the 4-year
follow-up were also evaluated.
2.3. Analytical cohorts
The cohort for efﬁcacy analyses included subjects who received
three doses within protocol-deﬁned windows, whose timing
between doses was respected (21–90 days between doses 1 and
2; 90–210 days between doses 2 and 3), who  were HPV DNA  nega-
tive at Months 0 and 6 for the HPV type considered in the analysis,
who did not have a biopsy or treatment (loop electrosurgical exci-
sional procedure) during the vaccination phase, for whom there
was no investigational new drug safety report during the vaccina-
tion period, and who  otherwise complied with the protocol during
the vaccination period (Fig. 1). The cohort for safety was deﬁned
as subjects who received at least one dose of vaccine and therefore
represents the intention to treat cohort (N = 7466). The cohort for
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3,727 HPV Ar 3m ,739 Control Ar m
1,084 Women Excluded
- 762 due to number of doses not exactly 3 
1 due to 
1,042 Women Excluded
- 716 due to number of doses not exactly 3 
2,643 women included in analyses for oncogenic HPV 
outcomes
2,697 women included in analyses for oncogenic HPV 
outcomes
8 Excluded
- 6 due to HPV-16 and -18 DNA at enrollment
- 2 due to HPV-16 and -18 DNA by 6 months 
20 Excluded 
- 10 due to HPV-16 and -18 DNA at enrollment
- 10 due to HPV-16 and -18 DNA by 6 months  
2,635 women included in analyses for HPV-16/18 
outcomes
2,677 women included in analyses for HPV-16/18       
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mmunogenicity was deﬁned as subjects included in the immuno-
enicity subcohort who met  the criteria deﬁned for the efﬁcacy
ohort above and whose timing between the third vaccine dose
nd the extra visit was 30–60 days (N = 354 women for HPV-16
nalysis; N = 379 for HPV-18 analysis).
.4. Outcomes
The primary outcome for efﬁcacy was deﬁned as histopathologi-
ally conﬁrmed CIN2+ associated with HPV-16/18 cervical infection
etected by PCR in the cervical cytology specimen that led to col-
oscopy referral. Final histological diagnosis was  deﬁned based
n blinded review by a Costa Rican and a US pathologist, with
linded review by a third pathologist in instances where the ﬁrst
wo reviewers disagreed [11]. In secondary efﬁcacy analyses, we
valuated histopathologically conﬁrmed CIN2+ associated with
on-HPV-16/18 and any oncogenic HPV cervical infections (HPV
ypes 16,18,31,33,35,39,45,51,52,56,58,59,68/73) detected by PCR
n the cervical cytology specimen that led to colposcopy referral,
nd time to incident infection with HPV-16/18 cervical infections.
n exploratory efﬁcacy analyses, an alternative (referred to here-
fter as “exploratory” to distinguish it from the a priori deﬁnition
escribed above) deﬁnition of HPV type attribution to CIN2+ lesions
as used that considered evidence of HPV persistence preceding
eferral to colposcopy when attributing HPV types to lesions in
nstances when >1 HPV type was present in the cervical cytol-
gy specimen that led to colposcopy referral. We  also evaluated
istopathologically conﬁrmed CIN2+, irrespective of HPV type, in
n analysis that considered outcomes that occurred in the absence
f HPV during the vaccination period.
For safety analyses, solicited local and general adverse events
AEs) within 60 min  after vaccination (all subjects) or from
ay 3–6 post-vaccination (10% random subset) were evaluated.
nsolicited AEs, serious adverse events (SAEs), and pregnan-
ies/pregnancy outcomes were documented throughout the 4-year
tudy period. Impact of vaccination on pregnancies/pregnancy
osses was reported on separately [18] and is not considered here
ecause limited new blinded information on pregnancies around
accination was accrued after the initial report.For immunogenicity analyses, we evaluated presence and level
f HPV-16 and HPV-18 antibodies by ELISA and by HPV-16 V5 and
PV-18 J4 monoclonal antibody inhibition EIA measured during the
accination period, at one month after the last vaccination, and at cohort for efﬁcacy analyses.
annual visits thereafter in the subjects enrolled into the immuno-
genicity cohort.
2.5. Statistical analysis
Vaccine efﬁcacy (VE), deﬁned as the percentage reduction in an
endpoint due to the vaccine, was estimated as the complement of
the ratio of the attack rates (risk ratio) in the HPV and control arms.
The attack rate was calculated as the percentage of women  who
experienced the endpoint. The complement of the 95% conﬁdence
interval (95% CI) for the risk ratio was used to calculate the CI for
the VE estimates. The difference between the attack rates in the two
arms was  used to assess rate reductions. The CI for the difference
was calculated using the conditional exact test. Separate analyses
were conducted for HPV-16/18, all oncogenic HPV types combined,
all oncogenic HPV types combined excluding HPV-16/18, individual
HPV types, and irrespective of HPV type.
The proportion of subjects with at least one SAE classiﬁed by
International Classiﬁcation of Diseases Version 10 during the study
is presented by study group. Similar information is presented for
grade 3 (severe) SAEs and for SAEs classiﬁed by the local investi-
gator as possibly related to vaccination. We  report separately the
proportion of subjects with at least one reported autoimmune AE,
neurological AE or death.
Seropositivity rates and Geometric Mean Titers (GMTs) with 95%
CIs were calculated. When calculating GMTs, antibody titers below
the assay cut-off were given a value of half the cut-off.
3. Results
Participants in the HPV and control arms of the trial and included
in the ATP cohort for efﬁcacy were comparable with respect to age,
clinic, sexual behavior and HPV-16/18 serology and DNA results at
entry (Supplemental Table 1).
Supplementary Table 1 related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.vaccine.2014.
06.038.
Number of CIN2+ events, rates and efﬁcacy are presented in
Table 1. Efﬁcacy against incident HPV-16/18 associated CIN2+ was
89.8% (95% CI = 39.5–99.5; rate reduction = 3.4/1000 women) using
our a priori algorithm for HPV type attribution and 88.7% (95%
CI = 31.3–99.5; rate reduction = 3.0/1000 women) using the alterna-
tive (exploratory) deﬁnition that considers viral persistence when
5090 A. Hildesheim et al. / Vaccine 32 (2014) 5087–5097
Table 1
Vaccine efﬁcacy against CIN2+ outcomes – ATP cohort for efﬁcacy – Costa Rica HPV-16/18 vaccine trial (CVT).a
HPV type Arm Women in ATP
cohort, N
Women  with
CIN2+ events, n
Rate (per 1000
women)
Rate Reduction
(95% CIa)
Efﬁcacy, % (95% CIa)
HPV-16/18 HPV 2635 1 0.4
Control 2677 10 3.7 3.4 (1.0, 4.1) 89.8 (39.5, 99.5)
HPV-16/18 (exploratory) HPV 2635 1 0.4
Control 2677 9 3.4 3.0 (0.7, 3.7) 88.7 (31.3, 99.5)
Non-HPV-16/18 oncogenic HPV 2643 11 4.2
Control 2697 28 10.4 6.2 (1.7, 9.8) 59.9 (20.7, 80.8)
Non-HPV-16/18 oncogenic (exploratory) HPV 2643 5 1.9
Control 2697 24 8.9 7.0 (3.3, 9.3) 78.7 (47.1, 92.8)
Oncogenic HPV HPV 2643 11 4.2
Control 2697 33 12.2 8.1 (3.4, 11.7) 66.0 (34.0, 83.5)
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Control 2697 
a CIN2+, Cervical intraepithelial neoplasia 2 or more severe disease; ATP, accordi
aking HPV type attribution. A total of 11 HPV-16/18 associated
IN2+ events were observed using our a priori deﬁnition; 10 were
IN2 and one was a CIN3. The single HPV-16/18 CIN2+ event in
he HPV arm occurred in a participant who at entry had antibod-
es against both HPV-16 and HPV-18, and evidence (by DNA test)
f infection with a non-oncogenic HPV type (HPV-66), and who
as positive (by DNA test) for HPV-16 and -45 11 months after
nrollment and diagnosed with CIN3 15 months after enrollment.
fﬁcacy estimates against CIN2+ associated with non-HPV-16/18
ncogenic HPV types were 59.9% (a priori deﬁnition) and 78.7%
exploratory deﬁnition). The breakdown of HPV types detected by
rm is summarized in Fig. 2a (a priori deﬁnition) and b (exploratory
eﬁnition). Efﬁcacy estimates irrespective of HPV type were 61.4%
95% CI = 29.5–79.8; rate reduction = 8.4/1000 women; N = 37 in
ontrol arm and 14 in HPV arm) by our a priori and 75.3% (95%
I = 48.1–89.3; rate reduction = 9.2/1000 women; N = 33 in control
rm and 8 in HPV arm) by our exploratory deﬁnition of incident out-
omes. Results for individual oncogenic HPV types are summarized
n Supplemental Tables 2a and 2b.
Supplementary Tables 2a and 2b related to this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
014.06.038.
Efﬁcacy against incident HPV-16/18 infections during the study
as 79.5% (95% CI = 74.0–84.0; rate reduction = 115/1000 women)
Table 2). Efﬁcacy in this group of young adults was lowest in the
rst year of follow-up (57.1%; 95% CI = 33.2–73.0) and higher in
ubsequent years (82.6% in year 4+; 95% CI = 73.0–89.2).Safety ﬁndings are summarized in Table 3. Rates of solicited
ocal and general AEs were comparable in the two arms in the
our following vaccination. The rate of local solicited AEs within
–6 days following any vaccination was higher among those in
A B
ig. 2. (a) Distribution of CIN2+ outcomes by HPV type (a priori) and vaccination arm 
b) Distribution of CIN2+ outcomes by HPV Type (strict) and vaccination arm – according1.9
10.8 8.9 (5.1, 11.2) 82.4 (57.0, 94.0)
rotocol; 95% CI, 95% conﬁdence interval.
the HPV arm (53.7% for all; 1.8% for grade 3 AEs) compared to
the control arm (19.9% for all; 0.0% for grade 3 AEs). Unsolicited
AEs reported in the month following any vaccination were com-
parable between arms. The proportion of participants with SAEs,
SAEs possibly related to vaccination, medically signiﬁcant condi-
tions, new-onset chronic diseases, autoimmune AEs, neurological
AEs, and deaths were comparable between arms. All but 12 SAEs
possibly related to vaccination were pregnancy related [18]. For
the 12 remaining SAEs possibly related to vaccination, 7 occurred
in the HPV arm (1 Crohn’s disease, 1 ulcerative colitis, 1 rheumatoid
arthritis, 1 haematuria, 1 thyrotoxicosis, 1 excessive and frequent
menstruation with irregular cycle, and 1 somatoform autonomic
dysfunction) and 5 in the control arm (2 anaphylactic shock events,
1 generalized skin eruption, 1 acute appendicitis, and 1 unspeci-
ﬁed abnormality of gait/mobility). The 43 autoimmune events were
equally distributed across arms (22 in HPV arm; 21 in control arm)
and were due to goiter (8 in HPV arm; 9 in control arm), rheumatoid
arthritis (4 in HPV arm; 6 in control arm), inﬂammatory bowel dis-
ease (3 in HPV arm including 1 Crohn’s disease; 2 in control arm),
systemic lupus erythematosus (2 in HPV arm; 1 in control arm),
insulin-dependent diabetes mellitus (1 in HPV arm; 1 in control
arm) and other conditions (4 in HPV arm; 2 in control arm). The
15 deaths observed were equally distributed across arms (8 in HPV
arm; 7 in control arm) and were due to suicides (4 in control arm),
automobile accidents (1 in HPV arm; 2 in control arm), physical
assault (2 in HPV arm), cancer (1 in HPV arm; 1 in control arm),
Crohn’s disease (1 in HPV arm), systemic lupus erythematosus (1
in HPV arm), HIV-associated conditions (1 in HPV arm), and acute
myocardial infarction (1 in HPV arm).
Immunogenicity results are summarized in Fig. 3a–d. GMTs
peaked at one month following last dose, declined thereafter and
– according to protocol cohort for efﬁcacy – Costa Rica HPV-16/18 vaccine trial.a
 to protocol cohort for efﬁcacy – Costa Rica HPV-16/18 vaccine trial.a
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Fig. 3. (a) Kinetics of HPV-16 antibody response by vaccination arm.* (ELISA assay) – immunogenicity subcohort – Costa Rica HPV-16/18 vaccine trial (CVT). (b) Kinetics
of  HPV-18 antibody response by vaccination arm.* (ELISA assay) – immunogenicity subcohort – Costa Rica HPV-16/18 vaccine trial (CVT). (c) Kinetics of HPV-16 antibody
response by vaccination arm.* (V5–EIA assay) – immunogenicity subcohort – Costa Rica HPV-16/18 vaccine trial (CVT). (d) Kinetics of HPV-18 antibody response by vaccination
arm.*  (J4 – EIA assay) – immunogenicity subcohort – Costa Rica HPV-16/18 vaccine trial (CVT).
5092 A. Hildesheim et al. / Vaccine 32 (2014) 5087–5097
Fig. 3. (Continued ).
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Table  2
Vaccine efﬁcacy against incident HPV-16/18 detection by time since ﬁrst vaccination – ATP cohort for efﬁcacy – Costa Rica HPV-16/18 vaccine trial (CVT).a
Time Arm Women in ATP
cohort, N
Women with
HPV-16/18 events, n
Rate (per 1000
women)
Rate reduction
(95% CIa)
Efﬁcacy, % (95% CIa)
Overall HPV 2635 78 29.6
Control 2677 387 144.6 115.0 (102.3, 126.1) 79.5 (74.0, 84.0)
Year  1 HPV 2380 27 11.3
Control 2420 64 26.4 15.1 (7.5, 21.7) 57.1 (33.2, 73.0)
Year  2 HPV 2313 18 7.8
Control 2349 117 49.8 42.0 (34.5, 47.8) 84.4 (74.8, 90.7)
Year  3 HPV 2232 11 4.9
Control 2166 88 40.6 35.7 (29.1, 40.3) 87.9 (78.0, 93.8)
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bYear  4+ HPV 2421 22 
Control 2261 118 
a ATP, according to protocol; 95% CI, 95% conﬁdence interval.
emained relatively stable beyond 12–24 months post-vaccination.
y ELISA, we observed that 100% of vaccinated participants were
eropositive against HPV-16 and HPV-18 after three doses and
emained seropositive at the end of the 4-year follow-up period.
y EIA, we observed that 100% and 99.5% of vaccinated participants
ere seropositive against HPV-16(V5) and HPV-18(J4), respec-
ively, after three doses. At the end of the 4-year follow-up period,
able 3
ummary of safety outcomes – total vaccinated cohorta – Costa Rica HPV-16/18 vaccine t
HPV arm 
n 
Within 60 min following any vaccination (N = 3727 HPV & 3739 control arms)
Any solicited adverse event
All 2534 
Grade  3 32 
Solicited local adverse eventsb
All 1918 
Grade 3 25 
Solicited general adverse eventsc
All 1580 
Grade  3 8 
Within day 3–6 following any vaccination (N = 380 HPV & 376 control arms; 10% sample)
Any  solicited adverse event
All 358 
Grade 3 11 
Solicited local adverse eventsb
All 204 
Grade  3 7 
Solicited general adverse eventsc
All 344 
Grade  3 4 
Within 30 days following any vaccination (N = 3727 HPV & 3739 control arms)
Unsolicited adverse events
All 1638 
Grade  3 34 
Serious adverse events during entire study period (N = 3727 HPV & 3739 control arms)
Any  serious adverse events 912 
Serious adverse events possibly related to vaccination 53 
Medically signiﬁcant conditionsd 744 
New-onset chronic diseased 383 
Autoimmune adverse eventsd 22 
Neurological adverse eventsd 626 
Deaths 8 
a Four participants who erroneously received both vaccine types were assigned to their
o  serious adverse events.
b Solicited local adverse events included pain, redness and swelling.
c Solicited general adverse events included fatigue, myalgia, arthralgia, gastro-intestina
d Medically signiﬁcant conditions were deﬁned as grade 3 (severe) serious adverse eve
ompared with a pre-deﬁned list of potential chronic diseases derived from the medical d
f  new onset was based on blinded review of the reported symptoms and the subject’s p
vents  (e.g. systemic lupus erythematosus, thyroiditis), which excluded allergy-related ev
n  origin, was  used to identify new onset autoimmune diseases among events identiﬁed
elonging to the system organ class ‘nervous system disorders’.9.1
52.2 43.1 (35.0, 49.5) 82.6 (73.0, 89.2)
92.3% and 45.8% of vaccinated participants remained seropositive
against HPV-16(V5) and HPV-18(J4), respectively.4. Discussion
This report summarizes results from the ﬁnal ATP analy-
sis of the NCI-sponsored CVT under GlaxoSmithKline Biologicals’
rial (CVT).
Control arm
% n %
68.0 2519 67.4
0.9 27 0.7
51.5 1902 50.9
0.7 22 0.6
42.4 1543 41.3
0.2 6 0.2
94.2 339 90.2
2.9 2 0.5
53.7 75 19.9
1.8 0 0.0
90.5 335 89.1
1.1 2 0.5
43.9 1536 41.1
0.9 30 0.8
24.5 891 23.8
1.4 39 1.0
20.0 739 19.8
10.3 417 11.2
0.6 21 0.6
16.8 591 15.8
0.2 7 0.2
 original randomization arm (1 HPV arm; 3 control arm). These individuals reported
l symptoms, headache, rash, urticaria, and fever.
nts. As described previously [36], all adverse events reported during the trial were
ictionary for regulatory activities. Determination of whether a chronic disease was
re-vaccination medical history. A separate list, restricted to potential autoimmune
ents or isolated signs and symptoms and events not considered to be autoimmune
 as new onset chronic diseases. Neurologic adverse events are all preferred terms
5094 A. Hildesheim et al. / Vaccine 32 (2014) 5087–5097
Table 4
Summary of ﬁndings from randomized clinical trials of prophylactic virus-like particle human papillomavirus vaccines.
Bivalent vaccine trials (HPV-16/18 AS04-adjuvanted vaccine) Quadrivalent vaccine trials
(HPV-6/11/16/18 vaccine)
Costa Rica vaccine trial
(CVT)
Phase III; NCT00128661
Japan efﬁcacy trial [26]
Phase II;
NCT00316693/NCT00929526
PApilloma TRIal against
cancer in young adults
(PATRICIA) [6,28]
Phase III; NCT00122681
Pooled analysis from 2 to 3 studies
[9,37–39]:
-007: phase II; NCT n/a
-013 (FUTURE I): phase III;
NCT00092521
-015 (FUTURE II): phase III;
NCT00092534
Countries Community-based trial
(Guanacaste; Costa Rica)
Japan Multi-country trial
(Australia, Belgium, Brazil,
Canada, Finland, Germany,
Italy, Mexico, Philippines,
Spain, Taiwan, Thailand,
UK, and USA).
Multi-country trials (Australia, Austria,
Brazil, Canada, Colombia, Czech
Republic, Denmark, Finland, Germany,
Hong Kong, Iceland, Italy, Mexico, New
Zealand, Norway, Peru, Poland, Puerto
Rico, Russia, Singapore, Sweden,
Thailand, UK, USA)
Age  18–25 years 20–25 years 15–25 years 16–26 years
Total  enrolled subjects 7466 1046 18,729 18,174 (protocols 007, 013 and 015)
Analytical cohort ATP cohort for efﬁcacy:
received 3 doses within
protocol deﬁned windows,
HPV DNA negative for the
HPV type under
consideration at months 0
and 6, no biopsy or
treatment (loop
electrosurgical excisional
procedure) during the
vaccination phase, no
protocol violation
ATP cohort for efﬁcacy: received 3 doses
within protocol deﬁned windows, HPV DNA
negative for the HPV type under consideration
at months 0 and 6, seronegative for the HPV
type under consideration at month 0, normal
or  low-grade cytology at month 0, no protocol
violation
Per-protocol: received 3 doses within 1
year, PCR negative and seronegative to
HPV-6, HPV-11, HPV-16, or HPV-18 at
enrolment, remained PCR negative to
the same vaccine HPV type (s), to
which they were naive at enrolment,
through 1 month post-dose 3, no
protocol violation
Endpoints CIN2+: CIN2, CIN3,
adenocarcinoma in situ or
invasive carcinoma
CIN2+: CIN2, CIN3,
adenocarcinoma in situ
or invasive carcinoma
CIN2+: CIN2CIN3,
adenocarcinoma in situ or
invasive carcinoma
CIN2 or worse
Follow-up 48 months post-dose 1 48 months post-dose 1 48 months post-dose 1 42 months post-dose 1
Efﬁcacy estimates
HPV16/18 types Current manuscript Konno et al., 2014 [26] Lehtinen et al., 2012 [6] Kjaer et al., 2009 [37]
Vaccine Control Vaccine Control Vaccine Control Vaccine Control
N 2635 2677 406 404 7338 7305 7864 7865
Cases 1 10 0 5 5 97 2 110
Efﬁcacy (95% CI) 88.7% (31.3, 99.5)a 100% (−8.0, 100) 94.9% (87.7, 98.4) 98.2% (93.3, 99.8)b
Non-vaccine oncogenic types HPV-31, -33, -35, -39,
-45, -51, -52, -56, -58,
-59, -68/73 [Current
manuscript]
HPV-31, -33, -35, -39,
-45, -51, -52, -56, -58,
-59, -66, -68/73 [26]
HPV-31, -33, -35, -39,
-45, -51, -52, -56, -58,
-59, -66, -68/73 [28]
HPV-31, -33, -35, -39,
-45, -51, -52, -56, -58,
-59 [38,39]
Vaccine Control Vaccine Control Vaccine Control Vaccine Control
N 2643 2697 444 435 8067 8047 4616 4680
Cases 5 24 4 12 88 165 62 93
Efﬁcacy (95% CI) 78.7% (47.1, 92.8)a 67.7% (−6.6, 92.4)c 46.8% (30.7, 59.4) 32.5% (6.0, 51.9)d
Irrespective of HPV Current manuscript Konno et al., 2014 [26] Lehtinen et al., 2012 [6] Munoz et al., 2010 [9]
Vaccine Control Vaccine Control Vaccine Control Vaccine Control
N 2643 2697 254 251 5466 5642 4616 4680
Cases  8 33 3 11 61 172 77 136
Efﬁcacy (95% CI) 75.3% (48.1, 89.3)a 73.9% (1.1, 95.3)e 64.9% (52.7, 74.2)e 42.7% (23.7, 57.3)d
ATP, according to protocol; CI, conﬁdence interval; CIN2+, cervical intraepithelial neoplasia 2 or more severe disease; n/a, not available; N, number of women in each arm
considered in the analysis; TVC, total vaccinated cohort.
a Vaccine efﬁcacy using exploratory deﬁnition described in Section 2.
b Vaccine efﬁcacy against HPV-6/11/16/18–related types for the quadrivalent vaccine.
c Vaccine efﬁcacy in the ATP cohort for efﬁcacy, regardless of baseline serostatus.
d Vaccine efﬁcacy restricted to subjects who received ≥1 vaccine dose and, at enrolment, were HPV DNA negative for vaccine and nonvaccine types (31, 33, 35, 39, 45, 51,
52,  56, 58 and 59), seronegative for HPV-6, -11, -16 and -18, and had normal cytology.
e Vaccine efﬁcacy in the TVC-naive cohort, i.e. women  who received ≥1 vaccine dose and, at baseline, were HPV DNA negative for vaccine and nonvaccine types (31, 33,
35,  39, 45, 51, 52, 56, 58, 59, 66 and 68/73), seronegative for HPV-16 and -18, and had normal cytology.
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T. Schiller (JTS; HPV virologist), Mark Sherman (QC pathologist),
Diane Solomon (medical monitor & QC pathologist), Sholom
Wacholder (statistician).A. Hildesheim et al. / Va
DA-BB-IND-7920. Our results conﬁrm the high efﬁcacy of
LP-based vaccines against incident CIN2+ associated with
PV-16/18 [4–10]. It is reassuring that high efﬁcacy against infec-
ions and lesions associated with the HPV types in the vaccine
ormulation has now been reported for VLP-based vaccines from
ultiple trials conducted in different populations, despite differ-
nces in study methodology [4–10,26,27] (Table 4). Furthermore,
ur report is consistent with previous results suggesting that vacci-
ation with the HPV-16/18 vaccine might confer partial protection
gainst some oncogenic HPV types not included in the vaccine
ormulation [28]. We observed 60% efﬁcacy against CIN2+ associ-
ted with incident oncogenic HPV infections with types other than
PV-16/18, an effect that increased to near 80% when we  consid-
red evidence of HPV persistence preceding referral to colposcopy.
lthough limited by small numbers, our ﬁndings suggest some efﬁ-
acy (point estimates ranging from 42% to 100%) for all HPV types
hylogenetically related to HPV-16 (A9 species – including HPV
ypes 31,33,35,52,58). For HPV types phylogenetically related to
PV-18 (A7 species – including HPV types 39,45,59,68), evidence
as mixed, with suggestion for efﬁcacy against HPV-68 (which
n our testing system was indistinguishable from non-oncogenic
PV-73) but not for other types related to HPV-18. Finally, when
IN2+ cases were examined irrespective of HPV type, we observed
ver 60% efﬁcacy, an effect that increased to >75% when our
xploratory criteria were used to deﬁne incident outcomes. It is
mportant to note that such estimates of overall efﬁcacy are likely
o be population speciﬁc and to vary depending on the propor-
ion of infections in the population attributable to vaccine types,
on-vaccine HPV types for which there is cross-protection, and
on-vaccine HPV types for which there is no cross-protection. In
act, vaccine efﬁcacy against non-vaccine types or irrespective of
PV type reported from phase III randomized clinical trials to
ate have varied considerably as summarized in Table 4. It is not
ully understood to what extent these observed differences are
ue to differences in study design and analysis (e.g. differences
n colposcopy algorithm, sensitivity/speciﬁcity of HPV assays, and
nalytical cohorts evaluated), chance (95% conﬁdence intervals
end to overlap), population differences (e.g. differences in relative
istribution of non-vaccine HPV types in different study popula-
ions), or vaccine differences (i.e. real differences in cross protection
etween the bivalent and quadrivalent vaccines). In a recent eval-
ation of this issue, we have noted that differences observed in
fﬁcacy estimates between FUTURE I/II and PATRICIA are likely
xplained by a combination of these various factors [23].
We saw no evidence of waning efﬁcacy during the study period.
hen we evaluated efﬁcacy against HPV-16/18 infection over time,
igh efﬁcacy (>80%) was observed in years 2–4+ and the lowest
fﬁcacy estimate was observed in the ﬁrst year of follow-up (57%).
he high efﬁcacy observed in the out years is consistent with evi-
ence of long-term protection up to 8.4 years (HPV-16/18 vaccine)
nd 5 years (HPV-6/11/16/18 vaccine) in the pharmaceutical trials
29,30]. We  interpret the somewhat reduced efﬁcacy in year 1 as
uggestive that some outcomes might have resulted from unde-
ected infections present before vaccination in our group of largely
exually experienced women [12].
The safety and immunogenicity proﬁle of VLP-based vaccine
ave been evaluated in large-scale trials and results suggest that
hat vaccine has an acceptable safety proﬁle, is generally well tol-
rated, and induces a robust and sustained immune responses
7,30–35]. Safety results from our trial are consistent with these
revious reports. Similarly, consistent with previous reports, we
oted robust antibody levels (measured by ELISA) following vac-
ination that persisted throughout the four years of follow-up –
00% of participants evaluated were seropositive against HPV-16
nd HPV-18 at the end of follow-up. This is consistent with the high
linical efﬁcacy observed. By the EIA inhibition assay that targets 32 (2014) 5087–5097 5095
neutralizing epitopes for HPV-16 and HPV-18, we also observed
robust responses following vaccination. These responses were
measurable after four years for nearly all participants evaluated
for HPV-16 (92.3%) and for roughly half of participants evaluated
for HPV-18 (45.8%). Since efﬁcacy remained high throughout the
four years of follow-up for both HPV-16/18, the fact that about half
of the vaccinees sero-reverted to HPV-18 by the EIA assay suggests
that protective levels are lower than the minimum detectable level
by the assay or that antibodies against additional epitopes can also
be protective.
Limitations of our trial include the modest number of CIN2+
events among women  naïve to speciﬁc HPV types during the vacci-
nation period, which limited our ability to evaluate efﬁcacy against
individual HPV types other than HPV-16/18 and against CIN3+. Our
study size also limited the ability to evaluate efﬁcacy against lesions
by time.
A distinguishing characteristic of our trial is its community-
based design; we  enrolled women from a well-deﬁned area based
on a census [11]. As a result, our trial represents a unique large-scale
community-level trial conducted pre-licensure and affords an
opportunity for follow-up studies to address many questions
of interest. These include questions regarding long-term safety,
immunogenicity and efﬁcacy; natural history of infections in vac-
cinated women  and the impact of vaccination on cervical disease
associated with non-vaccine HPV types; the impact of vaccina-
tion on screening; and the utility of novel screening tools in
vaccinated populations. The results presented herein serve as a
benchmark to help interpret results from some of these planned
efforts.
Our ﬁndings provide additional independent evidence of the
efﬁcacy, immunogenicity and safety of the HPV-16/18 vaccine for
prevention of HPV infections and cervical cancer precursor lesions
in previously unexposed women  and further support the estab-
lishment of vaccination programs that target individuals prior to
exposure.
Note: Cervarix is a registered trademark of the GlaxoSmithKline
group of companies.
5. Investigators in the Costa Rica vaccine trial (CVT) group
Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San
José, Costa Rica—Mario Alfaro (cytopathologist), M.  Concepción
Bratti (co-investigator), Bernal Cortés (specimen and repository
manager), Albert Espinoza (head, coding and data entry), Yenory
Estrada (pharmacist), Paula González (co-investigator), Diego Guil-
lén (pathologist), Rolando Herrero1 (co-principal investigator),
Silvia E. Jiménez (trial coordinator), Jorge Morales (colposcopist),
Lidia Ana Morera (head study nurse), Carolina Porras (co-
investigator), Ana Cecilia Rodríguez (co-investigator), Luis Villegas
(colposcopist).
University of Costa Rica, San José, Costa Rica—Enrique Freer
(director, HPV diagnostics laboratory), José Bonilla (head, HPV
immunology laboratory).
United States National Cancer Institute, Bethesda, MD,
USA—Allan Hildesheim (co-principal investigator & NCI co-
project ofﬁcer), Aimée R. Kreimer (co-investigator), Douglas R.
Lowy (DRL; HPV virologist), Nora Macklin (trial coordinator),
Mark Schiffman (medical monitor & NCI co-project ofﬁcer), John1 Present address: Prevention and Implementation Group, International Agency
for  Research on Cancer, World Health Organization, 150 Cours Albert Thomas, 69372,
Lyon, France.
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SAIC, NCI-Frederick, Frederick, MD,  UDA—Ligia Pinto (head, HPV
mmunology laboratory), Troy Kemp (immunologist).
Georgetown University, Washington, DC, USA—Mary Sidawy
histopathologist).
DDL Diagnostic Laboratory, Netherlands—Wim Quint (virolo-
ist, HPV DNA testing), Leen-Jan van Doorn (HPV DNA testing).
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